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Object. The optimal management of glomus jugulare tumors remains controversial. Available treatments were once 
associated with poor outcomes and significant complication rates. Advances in skull base surgery and the delivery of 
radiation therapy by stereotactic radiosurgery have improved the results obtained using these treatment options. The 
authors summarize and compare the contemporary outcomes and complications for these therapies.
Methods. Papers published between 1994 and 2004 that detailed the use of radiosurgery or surgery to treat glomus 
jugulare tumors were reviewed. Eight radiosurgery series including 142 patients and seven surgical studies including 
374 patients were evaluated for neurological outcome, change in tumor size (radiosurgery) or percent of total resec­
tion (surgery), recurrences, tumor control, need for further treatment, and complications.
The mean age at treatment for patients who underwent surgery and radiosurgery was 47.3 and 56.7 years, respec­
tively. The mean follow-up duration was 49.2 and 39.4 months, respectively. The surgical control rate was 92.1%, with 
88.2% of tumors totally resected in the initial surgery. A cerebrospinal fluid leak occurred in 8.3% of patients who 
underwent surgery and recurrences were found in 3.1%; the mortality rate was 1.3%. Among patients who underwent 
radiosurgery, tumors diminished in 36.5%, whereas 61.3% had no change in tumor size, and subjective or objective 
improvements occurred in 39%. Despite the presence of residual tumor in 100% of radiosurgically treated patients, 
recurrences were found in only 2.1%, the morbidity rate was 8.5%, and there were no deaths.
Conclusions. Death and recurrences after these treatments are infrequent, and therefore both treatments are consid­
ered to be safe and efficacious. Although surgery is associated with higher morbidity rates, it immediately and totally 
eliminates the tumor. The radiosurgery results are very promising, although the incidence of late recurrence (after 
10-20 years) is unknown.
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Glomus jugulare tumors are rare, with an estimated in­
cidence of one per 1.3 million population.33 These tumors 
are typically radiosensitive, highly vascularized lesions 
arising from the chief cells of the paraganglia in the ad­
ventitia of the dome of the jugular bulb. Although only 1 
to 5% are malignant and exhibit metastatic spread,3,4,6,32 the 
more common benign tumors are often locally aggressive 
and are associated with compression and infiltration of 
adjacent bone, cranial nerves, or blood vessels,10 despite 
an estimated growth rate of only 0.8 mm per year.5,25
Early attempts to treat these benign, slow-growing le­
sions surgically were associated with poor local tumor 
control, high rates of recurrence, and significant levels of 
morbidity and mortality.24 In 1973, Rosenwasser41 noted a 
recurrence rate of 80% and a mortality rate of 50% after 
surgery for paragangliomas involving the skull base. In re­
ports published in 197341 and 1983,40 separate investiga­
tors noted that the standard treatment for glomus jugulare 
tumors was a radical mastoidectomy, that complete exci­
sion was seldom possible, and that radiotherapy was com-
Abbreviations used in this paper: CSF = cerebrospinal fluid; 
GKS = gamma knife surgery; ICA = internal carotid artery; LINAC = 
linear accelerator; MR = magnetic resonance.
monly used for residual or unresectable disease. Since that 
time, advances in neuroimaging, in the understanding of 
the surgical anatomy related to glomus jugulare tumors, in 
microsurgical techniques, and in the delivery of radiation 
have improved treatment efficacy and safety. Today, the 
treatment options for patients with glomus jugulare tu­
mors include microsurgical resection, radiosurgery, vascu­
lar embolization, conventional fractionated external-beam 
radiotherapy, or a combination of these modalities. The 
goal of any treatment is to control tumor growth and pre­
vent further neurological compromise, and it is important 
select the intervention with the greatest chance of tumor 
control and the lowest risk of complications.
For many patients the primary treatment modality for 
these lesions is surgery, and it is the only treatment option 
that can offer immediate and complete tumor elimination. 
Although the goal of surgery is total resection, because of 
their vascularity and the involvement of critical vascular 
and neural anatomy in glomus jugulare tumors, the total 
removal of these lesions has been accompanied historical­
ly by significant morbidity, including new cranial nerve 
deficits and occasionally death. Nevertheless, the ability 
to combine various skull base approaches, along with 
advances in microneurosurgical techniques, anesthesia,
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postoperative care, nerve grafting, embolization, cranial 
nerve intraoperative monitoring, and preoperative evalua­
tion with cerebral blood flow studies have increased the 
possibility of achieving a total resection with fewer com­
plications. With current techniques, large lesions, tumors 
involving cranial nerves, or complex glomus jugulare tu­
mors that were deemed inoperable in the past and were 
treated with radiotherapy as a primary modality are being 
safely and totally resected.1'219'243536'53
Conventional radiotherapy with fractionated external- 
beam radiation has been used as a primary, combined, or 
salvage treatment in patients who cannot undergo surgery 
because of advanced age or other comorbidities, more 
aggressive, larger, or unresectable tumors, or residual dis­
ease. Its use, however, is associated with frequent recur­
rences at lower radiation doses,17'2739'44'45'47 and with signif­
icant radiation-induced complications at higher doses.1014, 
w 8,42,44,49 These complications include radiation-induced 
otitis, mastoiditis, altered taste sensations, alopecia, mu­
cositis, and dermatitis, all of which may occur acutely. 
Other complications that have been reported to occur in 
a delayed manner have included facial nerve palsy, hear­
ing loss, temporal bone necrosis, brain necrosis, second­
ary malignancy including osteosarcoma, late metastasis to 
bone and lungs 17 years after radiation therapy, CSF leak­
age from radiation-induced dural and temporal bone 
necrosis, and pituitary/hypothalamic insufficiency.101416, 
wm2,44,49 It is important to note that the goal of radio­
therapy is disease control or growth inhibition rather than 
tumor elimination,43 because higher doses of radiation are 
associated with increased complications involving the 
temporal bone and brainstem.9 Radiation therapy has been 
noted to eliminate the entire tumor in only 30% of cases.47 
Interestingly, the mechanism of growth inhibition of glo­
mus jugulare tumors by radiotherapy is not entirely un­
derstood. It is thought to work by inducing perivascular fi­
brosis, but many tumors continue to exhibit significant 
vascularity on angiographic studies obtained after radio­
surgery, despite decreased growth. Furthermore, unlike 
the vessels, the tumor (chief) cells are radioresistant and 
persist after radiotherapy.20'2930'42'43'46
Recently, reports of the use of GKS and LINAC stereo­
tactic radiosurgery as primary and secondary treatment 
modalities for glomus jugulare tumors have increased.1012, 
l4'l5'26'28-3l'37'42 Glomus jugulare tumors are well demarcated 
on MR images and rarely invade the brain, which makes 
them ideal candidates for treatment with radiosurgery 
because it allows a steep dose decrease at the margin.42 
Compared with conventional radiotherapy, radiosurgery 
involves a shorter treatment time, precise stereotactic lo­
calization, and a small volume of irradiated normal tissue; 
thus, the incidence of complications is lower.14,42 Propo­
nents of the use of radiosurgery as a primary modality 
argue that it has the potential to avoid the hospital costs 
and potential postoperative morbidity associated with 
surgery, providing a more cost-effective treatment.14,42 
Radiosurgical treatment usually takes 1 day, or in rare 
cases 2 days, compared with 4 to 6 weeks for convention­
ally fractionated external-beam radiation, and with sever­
al weeks of postoperative recovery for resection.14
As more outcome data for radiosurgery become avail­
able, it is important to evaluate which treatment modality
is associated with the best outcomes, fewest recurrences, 
and fewest complications. Various authors have compared 
conventional radiotherapy with surgery.7'10'48'49'51 Carrasco 
and Rosenman7 evaluated 24 series that included a total of 
582 patients and found that after surgery as opposed to 
radiotherapy as a primary treat-ment, 6% compared with 
11% of patients had residual tumors, 7% compared with 
8% had tumor recurrences, and the death rate was 2.5% 
compared with 6%. Conversely, Springate and colleagues 
in 199148 reviewed the literature published between 1965 
and 1988 and found that the control rate for surgery alone 
was 86%, whereas that for radiation alone was 93%. In 
that report, the follow-up duration for the surgery series 
was usually more than 7 years, but the duration of follow 
up for the patients treated with radiotherapy alone was not 
reported. To our knowledge, the outcomes of radiosurgery 
and surgery have not been directly compared.
Our goal in this paper was to evaluate the most recent 
literature to determine which modality, surgery or radio­
surgery, is the most effective for tumor control and the 
safest. Additionally, the literature was evaluated to deter­
mine whether individual tumor and patient characteristics, 
including the patient’s age and degree of neurological im­
pairment and the lesion’s growth rate and size make one 
treatment modality more appropriate than the other.
LITERATURE REVIEW
This study involved a retrospective literature review of 
English-language articles listed in Medline that referenced 
the primary treatment of glomus jugulare tumors with 
radiosurgery or surgery, with attention focused on the 
larger series and those published between 1994 and 2004. 
A total of 10 radiosurgery articles fit this criteria, although 
two of these were smaller series10,14 and their data were 
included in later studies.1115 Therefore, eight radiosurgery 
studies comprising 142 patients were evaluated for this 
study. Seven surgical articles met the criteria and they 
included 374 patients. Every attempt was made to include 
only patient data from glomus jugulare tumors and to ex­
clude data from glomus tympanicum, glomus vagale, or 
other paraganglia tumors. When a series included some 
patients with these other tumors, a notation was made. In­
terestingly, in radiosurgery series all patients were report­
ed to have glomus jugulare tumors.
The following parameters were evaluated: tumor size, 
distribution of tumor extent according to the Fisch13 and 
Glasscock-Jackson23 staging systems, neurological out­
come, change of tumor size for radiosurgery/percentage 
with total resections for surgery, recurrences (radiograph- 
ically or clinically confirmed), tumor control, need for fur­
ther treatment, and complications.
Classification Systems
Series in which the Fisch or Glasscock-Jackson clas­
sification of the tumors were noted are listed in Table 1 
for comparison. The Fisch13 system classifies five types 
of tumors: Class A lesions are limited to the middle ear 
cleft, Class B tumors are limited to the tympanomastoid 
area without infralabyrinthine compartment involvement, 
Class C are tumors involving the infralabyrinthine com-
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TABLE 1
Two classification systems for glomus jugulare tumors 
treated with radiosurgery or surgery*
No. of Patients/Classification
Authors & Year Fisch Glasscock-Jackson
radiosurgery
Eustacchio, et al., 1999 3/C, 5/D1, 2/D2 3/II, 4/III, 3/IV
Liscak, et al., 1999 36/B or C, 27/C, 17/D NA
Jordan, et al., 2000 3/B, 3/C1, 1/D1, 1/? NA
Saringer, et al., 2001 8/De1, 1/De2, 4/Di1 NA
Eustacchio, et al., 2002 4/C2, 12/D1, 3/D2 7/II, 6/III, 6/IV
Maarouf, et al., 2003 1/C, 11/D1 or D2 NA
surgery
Green, et al., 1994 24/B, 13/C, 15/D NA
Patel, et al., 1994 1/B, 11/C or D 4/II, 1/III, 7/IV
Whitfield, et al., 1996 4/B, 5/C, 6/D NA
Jackson, et al., 2001 NA 27/I, 26/II, 44/III,
29/IV
Pareschi, et al., 2003 25/C, 8/D1, 4/D2 NA
* Not all studies provided this information. See Classification Systems 
for explanation of designations. Abbreviations: De1 and De2 = extradural 
Class D1 and D2; Di1 = intradural Class D1; NA = not available; ? = tumor 
not classified.
partment of the temporal bone and extending into the 
petrous apex, Class D1 are tumors with an intracranial 
extension less than 2 cm in diameter, and Class D2 are tu­
mors with greater than 2-cm-diameter intracranial exten­
sion. Variants of this classification were used in some of 
the series reviewed in this paper. For example, “Di” refers 
to tumors with intradural extension, whereas “De” refers 
to those with extradural extension. For the Glasscock- 
Jackson classification, Grade I refers to a small tumor in­
volving the jugular bulb, middle ear, and mastoid; Grade
II is a tumor extending under the internal auditory ca­
nal; Grade III is one extending into the petrous apex; and 
Grade IV is one extending beyond the petrous apex and 
into the clivus or infratemporal fossa. Grades II, III, or IV 
may exhibit intracranial extension.
RESULTS
Radiosurgery Series
Demographic Data and Prevalence of GKS Compared 
With LINAC Therapy. Of the eight radiosurgery series 
evaluated (Table 2), stereotactic GKS was used in five 
(62.5%) and a frame-based LINAC system was used in 
three (37.5%).10-12,14,15,26,28,30,31,42 In one of the studies in 
which LINAC was used primarily, four patients were 
treated with the CyberKnife.28 A total of 143 patients who 
were treated with radiosurgery were described. All pa­
tients received their treatments between 1990 and 2001. 
Sixty-nine (48%) of 143 received radiosurgery as a pri­
mary treatment and 74 (52%) had undergone other ther­
apies prior to radiosurgery. Across all of these studies, the 
mean age at treatment was 56.7 years (range 44-63.5 
years) and the mean duration of follow up was 39.4 
months (range 20-86.4 months).
The tumor size after treatment was reported for 137 pa­
tients. Tumors were evaluated after radiosurgery by using 
axial, coronal, and sagittal MR images to measure the
largest dimensions of each lesion in the x, y, and z axes. 
Any change in any dimension was scored as tumor growth 
or reduction. After treatment with stereotactic radiosurg­
ery, at the latest follow-up review, the tumor size had de­
creased in 50 (36.5%) of 137 lesions, and there was no 
change in size in 84 (61.3%) of 137. There was no case of 
total elimination of the tumor. The timing of the first ob­
servation of a decrease in tumor volume was documented 
in only one study,30 and the percentage of tumor shrink­
age was reported in only one study.31 A decrease in tumor 
volume was observed as early as 6 months after radio­
surgery and the median time reported was 20 months.30 
Maarouf and colleagues reported tumor shrinkage that 
ranged from 25 to 74% compared with the volume noted 
on preradiosurgery scans in eight patients. Three patients 
(2.2%) had new tumor growth after radiosurgery; this 
growth was observed at 6, 40, and 84 months.1112 The 
cases of recurrence are discussed later.
Neurological Outcome. The neurological outcome was 
reported for 141 patients; it was determined by an objec­
tive change in patients’ physical examination when this 
information was available, or if the information was not 
provided, it was based on changes in patients’ symptoms. 
An improvement was noted if a patient had one or more 
findings of resolution or decreased intensity of the follow­
ing symptoms: tinnitus, vertigo, headaches, or hearing 
loss. If there was partial recovery of a neurological deficit 
or cranial nerve function with improvements in speech, 
swallowing, voice quality, or shoulder strength, this was 
also considered to be a positive outcome.
In 82 (58.2%) of 141 patients, results of the neurologi­
cal examination remained stable, 55 (39%) of 141 showed 
improvement, and four (2.8%) of 141 had permanent 
worsening after radiosurgery according to their neurolog­
ical examination. One of the four patients with permanent 
worsening of symptoms was later found to have metasta­
tic disease.12 Improvements in hearing, tinnitus, or vertigo 
were first noticed by some patients at 1 to 6 months, and 
most patients who noted improvement realized it by 12
months.26,30
Complications. Overall, neurological complications oc­
curred in 12 (8.5%) of 141 patients, although nine of these 
cases (6.4%) were transient. In the report by Saringer and 
colleagues,42 two patients experienced transient facial or 
glossopharyngeal neuropathies due to delayed radiation 
injury, one at 1 month and the other at 1 year after radio­
surgery. Both conditions completely resolved within 6 
months after treatment with steroid drugs. In the afore­
mentioned study, the target volume and the administered 
dose were not associated with the incidence of cranial 
neuropathies. One patient in the study by Jordan, et al.,26 
experienced immediate onset of severe vertigo after radio­
surgery that resolved after 11 months. Two patients suf­
fered inflammatory complications of the inner ear.30 Four 
other patients experienced transient worsening of their 
preexisting cranial nerve deficits, tinnitus, or vertigo after 
radiosurgery that resolved without treatment.121528
The rate of permanent deficits associated with radio­
surgery was three (2.1%) of 141 patients.12,30,31 Liscak and 
colleagues30 described two patients with permanent wors­
ening, in one of whom facial nerve function deteriorat­
ed to House-Brackmann Grade II and hearing loss pro-
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TABLE 2
Literature review of patient information and outcomes after radiosurgical treatment of glomus jugulare tumors*



























Foote, et al., 1997t GKS 67.0 20.0 8.6 9 (5P, 4S) 2U, 7I 78 8U, 1r 11 0 0
Eustacchio, et al., GKS 52.4 37.6 6.4 10 (4P, 6S) 5U, 5I 50 6U, 4r 40 0 0
1999t
Liscak, et al., 1999 GKS 54.0 24.0 5.7 52 (24P, 28S) 35U, 15I, 2W 29 28U, 19r, 5L 40 0 3 trans, 2 perm
Jordan, et al., 2000 GKS 61.9 27.0 9.8 8 (5P, 3S) 4U, 4I 50 3U, 4r, 1L 57 0 1 trans
Saringer, et al., GKS 63.5 50.4 9.0 13 (4P, 9S) 6U, 6I, 1L 50 10U, 3r 23 0 2 trans
2001
Eustacchio, et al., GKS 56.0 86.4 5.2 19 (10P, 9S) 8U, 10I, 1L 53 11U, 7r, 1inc 37 1/18 0
2002t 




Foote, et al., 2002§ GKS 62.5 37.0 10.4 25 (12P, 13S) 10U, 15I 60 17U, 8r 32
(40)
0 1 trans
Lim, et al., 2003 CK/LINAC 44.0 26.0 NA 9 (4P, 5S) 9U 0 8U, 1r 11 0 1 trans
Maarouf, et al., LINAC 59.0 48.0 12.2 12 (6P, 6S) 8U, 3I, 1W 25 4U, 8r 67 0 1 perm
2003
* CK = Cyberknife; FU = follow up; I = improved; inc = increased; L = lost to follow up; P = primary treatment; perm = permanent; r = reduced; S = sec­
ondary treatment; trans = transient; U = unchanged; W = worse. 
t  Data from this study were not included in the overall review because these results were included in the larger series published by the same primary author. 
t  Series included the 10 patients from Eustacchio, et al., 1999.
§ Series included the nine patients from Foote, et al., 1997.
gressed to deafness over 12 months. The other patient’s 
facial nerve function deteriorated to Grade IV and vertigo 
worsened at 6 months. Maarouf and colleagues31 had one 
patient in whom facial weakness developed 6 months after 
radiosurgery. No deaths were associated with the use of 
radiosurgery.
Additional Therapy. In several series, patients under­
went additional surgery (one patient), embolization (four 
patients), or further radiosurgery (five patients) after their 
initial radiosurgical treatment, although in these cases 
there was no evidence of radiographically or clinically 
confirmed recurrence at the time of the additional treat­
ments, and many were treated for persistent tinnitus.10,
11,30,31 After a mean follow-up duration of 39.4 months, 
three (2.2%) of 137 patients with complete follow up ex­
perienced clinically or radiographically confirmed recur- 
rences.11,12 One patient had been treated with radiosurgery 
as a primary modality and had evidence of new disease at 
the field’s margin at 6 months posttreatment.12 This patient 
was treated with salvage radiotherapy and had no further 
disease progression or evidence of recurrence 21 months 
later. Another patient was treated with radiosurgery for re­
current disease and experienced another recurrence 40 
months postradiosurgery. She was subsequently found 
to have metastatic disease in her lymph nodes and no fur­
ther treatment was performed.12 Finally, one patient who 
was treated with radiosurgery after a partial resection suf­
fered a recurrence at 84 months that was thought to be due 
to undertreatment stemming from the inability to identify 
the whole tumor on computerized tomography planning 
studies.11
Radiosurgery as Primary Treatment. Although 69 of 
143 patients underwent radiosurgery as a primary mo­
dality, very few series provided data on these individuals 
separately.10,26 Typically, data were provided for all pa­
tients combined, and it was impossible to decipher the 
outcomes and complications in those who received radio­
surgery as a primary modality. In two series, reported by 
Eustacchio, et al.,10 and Jordan, et al.,26 eight patients re­
ceived radiosurgery as a primary treatment; tumor size 
remained the same for six (75%) and was reduced for two 
(25%), and the neurological outcome improved for the 
other four (50%) and remained the same for four (50%). 
Feigenberg and colleagues12 described one patient who 
experienced a recurrence after receiving radiosurgery as a 
primary treatment.
Radiosurgery as secondary Treatment. Radiosurgery 
was used as secondary therapy in 74 (52%) of 143 pa­
tients. Of these patients, 60.3% underwent surgery prior 
to radiosurgery, 15.1% had radiation therapy, and 24.6% 
underwent embolization (some of them had combinations 
of these treatments). Foote and coworkers15 found a reduc­
tion in tumor size after radiosurgery in seven of 12 pa­
tients who had previously undergone surgery. Again, in 
most series the authors did not document separate data for 
the patients who underwent other treatments that failed 
prior to radiosurgery.
Surgery Series
Demographic Data and Overview of Approaches. A
total of 374 patients were treated with 384 surgical proce­
dures in the seven series we evaluated (Table 3). All pa­
tients underwent surgery during the period from 1972 to
2000. Across all of these studies, the mean age at treat­
ment was 47.3 years (range 41.7-49 years) and the mean 
duration of follow up was 49.2 months (range 37.2-58.8 
months). Green, et al.,19 published the only series that in­
cluded previously untreated glomus jugulare tumors. Be­
tween 7.7 and 50% of patients had previously undergone 
surgery and between 5.5 and 18% had previously under-
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TABLE 3
Literature review of patient outcomes after surgical treatment of glomus jugulare tumors*
Mean New
Patient Total Time to CSF CN
Most-Used No. of No. of Age FU Resection Recurrence Recurrence Leak Deficit Mortality
Authors & Year Approach Patients Ops (yrs) (mos) (%) (%) (mos) (%) (%) (%)
Green, et al., 1994 infratemporal 52 54 47.7 47.0 44/52
(85)
0 3.8 NA 0
Patel, et al., 1994t transtemporal-
infratemporal
12 13 45.7 44.0 10/12
(83)
0 33.3 NA 0
Watkins, et al., 1994 posterolat 49 50 41.7 40.8 NA 0 NA 57 2/49
(4.1)
Whitfield, et al., transtemporal- 20 20 47.0 37.2 18/20 1/20 48 10.0 NA 0
1996§ infratemporal (90) (5)




mean 98 4.5 59 3/176
(1.7)t
Al-Mefty & Teixeira, infratentorial/pst 28 28 47.0 38.0 24/28 2/28 4** & 60 14.3 NA 0
2002t fossa or intrabulbar (86) (7.1)
Pareschi, et al., 2003 infratemporal 37 37 NA 58.8 (96) 0 8.1 NA 0
* CN = cranial nerve; pst = posterior.
t  Two additional patients died, but they had carotid body tumors. 
t  Series included complex glomus jugulare tumors.
§ Series included five glomus vagale tumors.
II Series included 27 glomus vagale tumors and three carotid body tumors.
** Recurrence occurred at 4 months in a patient with a malignant glomus jugulare tumor.
gone radiation treatment.24'35'36'52'53 Approximately 25% 
of patients underwent preoperative embolization,2,19,36,53 
but in the study by Pareschi, et al.,35 100% of patients 
had received embolization. Tumors were treated in single 
operation2'19'24'35'52'53 or with staged surgery.35,36 The ap­
proaches included lateral,24 posterolateral with posterior 
fossa craniectomy and infratemporal fossa approach,35,52 
infratemporal fossa approach (first stage) followed by 
petrooccipital transsigmoid approach (second stage),35 
jugulopetrosectomy,35 transtemporal-infratemporal,36,53 
subtemporal-infratemporal added to a transtemporal-in- 
fratemporal,36 transtemporal-infratemporal with a retro- 
sigmoid craniectomy and/or extreme-lateral transcondylar 
approach,36 infratentorial and posterior fossa,2 and intrab- 
ulbar dissection.2
Series With Complex Tumors. It is important to note 
that patients in two of these series2,36 had “complex glo­
mus jugulare tumors” as described by Al-Mefty and Te- 
ixeira, which include giant tumors, multiple paragan­
gliomas, malignancy, catecholamine secretion, previous 
treatment with adverse events such as sacrifice of the ICA 
that make surgical intervention more risky, prior radiation, 
or adverse effects from embolization. The rate of total 
resection of lesions in these series that included challeng­
ing tumors was 83 and 86%.
Series Without Complex Tumors. Overall, total resec­
tion was achieved on the first attempt in 254 (88.2%) of 
288 surgeries, although this number excluded cases from 
two series that did not provide enough information.35,52,53 
On evaluation of the series that did not include complex 
tumors, 85 to 96% of surgeries resulted in total resec-
tions.2,19,24,35,36,52,53 In a series by Jackson, et al.,24 all subto­
tal resections (18 [10%] of 182) were for Grade III or IV 
tumors and were planned based either on preoperative pa­
tient preference for preservation of cranial nerves or the 
ICA, or to perform palliative surgery in elderly patients.
Most of the subtotal resections occurred in Fisch Class D 
tumors, and some surgeons achieved total resections for 
Class C tumors in 100% of cases.35
The surgical control rate for the noncomplex tumor se­
ries ranged from 88.5 to 94.5%.19'24'36'53 Surgical control 
was defined as complete tumor elimination with no evi­
dence of residual or recurrent disease throughout the fol­
low-up period. For example, in the report by Green, et 
al.,19 two of eight patients with subtotally resected tumors 
underwent immediate repeated surgeries to remove the 
residual tumors; thus, only six (11.5%) of 52 patients re­
mained with residual disease, and tumor control was 
88.5%. After repeated surgeries for residual or recurrent 
disease, the surgical control rate was 92%.
Preservation of Cranial Nerves. Cranial nerve preser­
vation was most easily accomplished in smaller tumors 
and was as high as 80 to 95%.21,22,36 In one series,24 com­
plete removal of a glomus jugulare tumor without cranial 
nerve resection or a new deficit occurred in 31% of pa­
tients. In the aforementioned series, the ninth through 12th 
cranial nerves had to be resected in 34.6% of cases, and 
this was mostly because of tumor involvement in the low­
er cranial nerves at the pars nervosa of the jugular bulb. 
According to our review of the literature, one or more new 
cranial nerve deficits occurred in 22 to 59% of patients 
after surgery,8,18,24,52 whereas in another review new sev­
enth, ninth, or 10th cranial nerve dysfunction was noted in 
49 to 83% of patients.10 Jackson, et al.,24 found that al­
though it was necessary to sacrifice the seventh, ninth, and 
10th cranial nerves in 23, 63, and 59% of cases, respec­
tively, preoperative deficits existed only in 12, 21, and 
31%, respectively. In several recent series new deficits 
were noted in the seventh cranial nerve in 4.4 to 11% of 
cases, in the ninth in 26 to 42%, in the 10th in 13 to 28%, 
in the 11th in 25 to 26%, and in the 12th in 5 to 21%.19,21,24
Although almost all patients experience facial weak­
ness in the postoperative period after nerve transposition
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or grafting, functional outcomes in the facial nerve are 
improving with the currently available advanced micro- 
surgical techniques, use of facial nerve monitoring, and 
limiting of nerve transposition when possible.193653 For 
example, Green and coworkers19 noted recovery of func­
tion to House Grade I or II in 95% of patients on long­
term follow-up review, and Whitfield and colleagues53 
noted that only 25% of patients had facial nerve dys­
function on follow up. Patel and coworkers36 were able 
to maintain sensorineural hearing in 11 (91.7%) of 12 
patients.
Complications. The incidences of other morbidities or 
postoperative complications are listed in Table 4.2,19,24,35, 
36,52,53 The most common complications were CSF leak­
age (8.3%), aspiration (5.5%), wound infection/ischemia 
(5.5%), pneumonia (2.3%), and meningitis (2.1%). None 
of these complications resulted in long-term deficits or re­
quired rehospitalization after initial discharge.
Additional Therapy. Adjunctive procedures were re­
quired in some patients after surgery and included vo­
cal cord injection (10-25%), thyroplasty (8-10%), eye­
lid weights (percentage not available), cricopharyngeal 
myotomy (4%), tracheostomy (0-5.4%), gastrostomy 
(4-5%), lateral tarsorrhaphy (20%), and nasogastric tube 
feeding (8-30%).19,35,53 Whitfield, et al.,53 noted that 
patients in their series who had lower cranial nerve 
deficits did well after undergoing these adjunctive proce­
dures; for example, five patients with dysphonia attained 
a complete resolution after vocal cord injection or thyro- 
plasty. Patel and coworkers36 treated 10 patients who had 
swallowing difficulties postoperatively, and symptoms 
resolved in nine of them without the need for a feeding 
tube. Several authors noted that patients with preoperative 
ninth and 10th cranial nerve deficits had an earlier and 
greater improvement in swallowing after surgery than 
patients without preoperative deficits,8,36 and in another 
paper it was reported that morbidity related to these cra­
nial nerve deficits was greatly decreased by aggressive 
pre- and postoperative speech and swallowing therapy.54 
Another group noted a decrease in the need for tra­
cheostomy and gastrostomy tubes after surgery.54
As mentioned earlier, the overall incidence of CSF 
leakage was 8.3%, and was a significant complication 
associated with surgery for glomus jugulare tumors. The 
incidence of CSF leakage ranged from 3.8 to 10% in most 
series,19,24,35,52,53 although in the two series with more than 
50% of repeated surgeries the incidence was 14.3 to 
33.3%.236 The majority of CSF leaks resolved without the 
need for repeated surgical closure after being treated with 
conservative management or a lumbar drain.19,35,36 In the 
study by Whitfield and coworkers,53 two patients had to 
undergo additional surgery to repair CSF leaks. In one se­
ries, intracranial, transdural tumor extension was present 
in 36% of cases, and CSF leaks were encountered in 64% 
of procedures.24 The risk of CSF leakage was decreased 
with improvements in dural closure including reconstruc­
tion with a vascularized local, regional, or free flap, such 
as a temporoparietal fascia flap.24,36 With a good dural clo­
sure, in one series a decrease in the incidence of CSF leak­
age from 28 to 4.5% was found.24 Other practitioners low­
ered the risk of CSF leakage for large intradural tumors by 
performing staged procedures.35
TABLE 4
Complications after 384 surgeries for glomus jugulare tumor
Complication No. of Patients (%)
CSF leak 32 (8.3)
aspiration 21 (5.5)




cerebral hemorrhage 6 (1.6)
stroke 6 (1.6)
external ear infection 5 (1.3)
tympanic membrane perforation 4 (1.0)
pulmonary embolus 3 (0.8)
worsened ataxia 3 (0.8)
pneumothorax 3 (0.8)
osteomyelitis of temporal bone 2 (0.5)
hydrocephalus 2 (0.5)
seroma 2 (0.5)
deep vein thrombosis 1 (0.3)
myocardial infarction 1 (0.3)
tracheitis 1 (0.3)
Overall, there were five deaths related to surgery in 374 
patients, for a total mortality rate of 1.3%. The mortality 
rate after surgery ranged from 0 to 4.1%.2 192435,36,52,53 
Deaths occurred from stroke caused by ICA injury (two 
patients), intracerebral hemorrhage (one patient), and pul­
monary embolus (two patients).24,52 The incidence of 
stroke, hemorrhage, or pulmonary embolus in the litera­
ture was low, at 1.6, 1.6, and 0.8%, respectively (Table 4).
Tumor Recurrence. Recurrence of glomus jugulare tu­
mors after surgery was noted in 12 (3.3%) of 360 cases; 
the range in these series was 0 to 5.5%,2,19,2435,36,52,53 and the 
mean time to recurrence was 82.8 months.22453 For benign 
glomus jugulare tumors, recurrences were reported at a 
range of 25 to 273 months.22453 Al-Mefty and Teixeira2 de­
scribed a patient in whom they achieved total resection of 
a very extensive and malignant glomus jugulare tumor af­
ter failure of radiation therapy, and the tumor recurred 4 
months later. In the report by Jackson, et al.,24 nine of 18 
subtotally resected tumors recurred; five of these cases 
were treated with total resection, two were observed, one 
was treated with radiotherapy, and one was left untreated.
Pareschi and coworkers35 noted that 84% of their pa­
tients were sent home within 14 days of surgery, and in an­
other two studies the mean hospital stay was 10 days.19,54 
Green and colleagues19 noted that 85% of patients were 
able to resume fully all preoperative activities and to take 
care of themselves. In another study it was found that all 
patients who were able to live independently before surg­
ery continued to be independent.36 In another series, 70% 
of patients subjectively noted that they had an excellent 
functional outcome.53
DISCUSSION
Since the original description of glomus jugulare tu­
mors in the 1940s, there has been considerable controver­
sy regarding the best management of this disease. In the 
past, observation, surgery, and radiotherapy were all used 
as primary treatments for these lesions. One factor that 
makes selecting the appropriate treatment difficult is the
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variable growth rate and clinical course of these tumors. 
Although the majority are benign and slow-growing le­
sions, they are locally invasive and, if left untreated, they 
have the potential to progress to cause considerable cra­
nial nerve and brainstem injury in some patients. In the 
past, the main arguments against surgical intervention 
were the high percentage of incomplete resections and, 
more importantly, the high rates of morbidity and mortal­
ity. Surgeons, however, argued that this modality was the 
only one with which they could obtain a complete re­
moval of the tumor. Radiotherapy was criticized for the 
high exposure of normal neural tissue and bone to radia­
tion, resulting in considerable radiation-induced compli­
cations. Additional criticisms included the delay in the 
treatment’s effect and the fact that residual tumor re­
mained after a successful intervention.
Our review demonstrates that the treatment of glomus 
jugulare tumors is now safer and more efficacious than it 
has ever been. This improvement is most likely due to 
considerable advances in surgery and in the delivery of 
radiation by using stereotactic radiosurgery. In the surgical 
literature we reviewed, we found that 88.2% of tumors 
were totally resected on the first surgery, with a surgical 
control rate of 92.1%. Cranial nerve preservation im­
proved, the incidence of CSF leakage decreased, recur­
rences were noted in only 3.1% of patients, and the mor­
tality rate was 1.3%.
Among radiosurgical series, in 36.5% of patients the tu­
mors decreased in size, 61.3% of tumors stayed the same 
size, all patients (100%) had residual tumors, 39% of pa­
tients had subjective or objective improvements, recur­
rences were found in 2.1%, the morbidity rate was 8.5%, 
and there were no deaths. Interestingly, the question of 
whether one defines treatment success as a cure by total 
elimination of tumor (surgery definition) or growth inhi­
bition (radiosurgery definition) remains, and makes it dif­
ficult to compare these modalities.
The radiosurgery and surgery groups in this review 
were similar. The mean patient age in the surgery series 
was 47.3 years, compared with 56.7 years in the radio­
surgery series. The patients who underwent surgery were 
followed for 49.2 months and the patients treated with 
radiosurgery were followed for 39.4 months. It is signifi­
cant to note that, whereas all of the radiosurgery patients 
were treated in 1990 or later, many of the surgery patients 
were treated in the 1970s and 1980s, and therefore the 
overall results for the patients who were more recently 
treated with surgery may be even better than reported in 
this review. It is difficult to make any comparison or to 
draw any conclusion about the sizes or classifications of 
the tumors in these two groups because of the variability 
in the way the data were reported. Additionally, the cur­
rent classification systems do not account for various im­
portant surgical factors such as brainstem compression, 
degree of vascular involvement, or large tumor size.36
Nonetheless, the data support the fact that recurrence 
after either treatment is very low and is similar at 3 or 4 
years posttreatment, regardless of how one defines con­
trol. It will be interesting to analyze more long-term stud­
ies to see how recurrence rates compare at 10 and 20 
years, because both surgery and radiosurgery now have 
such promising results. Many authors argue that the true 
test of a cure cannot be confirmed until observation has
continued for at least 10 or 20 years. Liscak, et al.,30 warn 
that a 5-year follow-up period cannot be considered ade­
quate to judge the success of the treatment. It is well 
known that tumor cells persist after radiation therapy. 
Therefore, it will be very important to see whether pa­
tients who undergo radiosurgery, who all have persistent 
tumors despite growth stabilization or reduction, experi­
ence increased recurrences at 10 and 20 years compared 
with those treated surgically. For example, in the radio­
surgery study with the longest follow-up duration (mean 7 
years)11 there was a recurrence at 7 years. In a study in 
which patients were treated exclusively with radiation 
therapy,39 the authors found that the tumor control rate was 
90% at 10 years, but 73% at 25 years.
No deaths were associated with radiosurgery and the 
mortality rate secondary to surgery was a little more than 
1%. The biggest difference between surgery and radio­
surgery is the rate of morbidity. Although it is easy to 
compute the morbidity associated with radiosurgery 
(8.5%), it is difficult to establish the short- and long-term 
morbidity in surgically treated patients. These patients are 
faced with many possible complications (Table 4). Fur­
thermore, although it is safe to say that more than 8.5% of 
the surgical group will have a new cranial nerve deficit 
after surgery for larger tumors, the impact of this new def­
icit on a patient’s long-term outcome is difficult to inter­
pret in the surgical papers. Long-term cranial nerve func­
tional outcomes in patients with new deficits (aside from 
those involving the facial nerve) were not commonly re­
ported in the surgical series. The surgical series did report 
that when cranial nerve dysfunction occurred, the use of 
adjunctive procedures and rehabilitation resulted in lower 
associated morbidity from this new deficit, and that many 
patients eventually improved to preoperative status. Pro­
ponents of radiosurgery as a primary modality argue that 
it has the potential to avoid the hospital costs and poten­
tial postoperative morbidity associated with surgery, pro­
viding a more cost-effective treatment.14,42 As mentioned 
earlier, radiosurgical treatment usually takes 1 day, 2 days 
in rare cases, compared with a mean 10-day hospital stay 
after surgery and possibly more if rehabilitation is needed.
Surgery remains the treatment of choice in an otherwise 
healthy patient who desires the immediate cure of disease 
provided by a total resection. Al-Mefty and Teixeira2 have 
shown that even the most complex glomus jugulare tu­
mors can be totally resected with minimal complications. 
Other strong indications for surgery are severe cranial 
nerve palsies, tumors that are too large for radiosurgery, 
lesions that cause vascular insufficiency due to major arte­
rial encasement, or tumors that have significant intracra­
nial extension and are life threatening.50 Obviously, resec­
tion is more difficult in cases with brainstem compression 
or major encasement of arteries by tumor,36 and if a com­
plete resection cannot be guaranteed or if there is a high 
risk of neurological deficits or morbidity with a radical 
resection, then a subtotal resection can be performed to 
debulk the tumor and prevent further neurological com­
promise. After a subtotal resection, stereotactic radio­
surgery is a safe and effective option to treat residual tu­
mor. Finally, elderly patients or those with significant 
comorbidities may elect to undergo radiosurgery as a pri­
mary treatment modality.10 The same guideline applies to 
cases of recurrent glomus jugulare tumors.
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